Jacobs Levy Equity Management, Inc Arbutus Biopharma Corp Transaction History

Jacobs Levy Equity Management, Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 15, 2022	BUY	$1.88 - $2.88 $345,669 - $529,536	183,867 New	183,867 $351,000
Q2 2022 Aug 15, 2022	SELL	$1.98 - $3.17 $110,311 - $176,610	-55,713 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$3.11 - $4.61 $173,267 - $256,836	55,713 New	55,713 $217,000
Q3 2019 Nov 14, 2019	SELL	$1.34 - $2.4 $40,994 - $73,423	-30,593 Closed	0 $0
Q2 2019 Aug 13, 2019	BUY	$1.46 - $4.44 $12,843 - $39,058	8,797 Added 40.36%	30,593 $64,000

Q1 2019 May 14, 2019	BUY	$3.41 - $4.57 $74,324 - $99,607	21,796 New	21,796 $78,000

130

82.2M

4.82M

546K

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $489M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.